Physician profile
Eric I Hettler
NPI 1821248303
$8,725.49
in general payments reported to CMS, 2019-2025
39 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,015 · 2022: $1,271 · 2023: $2,248 · 2024: $2,881 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,331 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,330.79 |
| Education | $108.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,982.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,568.30 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,003.05 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $559.41 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $407.20 | 2023-2025 | |
| Glaxosmithkline, LLC. | $342.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $282.83 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.75 | 2022-2024 | Cycloset, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.70 | 2023-2025 | Jardiance, Synjardy |
| Avanir Pharmaceuticals, INC. | $238.38 | 2021-2022 | |
| Amgen INC. | $232.02 | 2023-2025 | Repatha, Otezla, Otezla |
| Axsome Therapeutics, INC. | $158.57 | 2022-2024 | Auvelity |
| Revance Therapeutics, INC. | $142.66 | 2025 | Daxi |
| Si-Bone, INC. | $141.89 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.40 | 2022-2024 | Caplyta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $102.87 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $100.13 | 2021-2025 | Steglatro, Belsomra, Gardasil 9 |
| Astellas Pharma US INC | $94.99 | 2023 | |
| Pfizer INC. | $78.14 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $65.83 | 2021 | |
| Corcept Therapeutics | $65.53 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $55.81 | 2023-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Kowa Pharmaceuticals America, INC. | $51.67 | 2021-2023 | Livalo, Seglentis |
| Halozyme INC | $47.52 | 2023 | |
| Idorsia Pharmaceuticals US INC | $41.94 | 2023 | Quviviq |
| Ardelyx, INC. | $40.95 | 2024 | Ibsrela |
| Antares Pharma, INC. | $38.25 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Exact Sciences Corporation | $33.74 | 2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $32.23 | 2023 | Edarbi |
| Mannkind Corporation | $29.95 | 2023 | Afrezza |
| Almatica Pharma LLC | $21.99 | 2024 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $19.89 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.63 | 2022 | |
| Alk-Abello, INC | $17.53 | 2024 | Grastek, Ragwitek, Odactra |
| Novartis Pharmaceuticals Corporation | $15.78 | 2023 | |
| Hikma Pharmaceuticals USA | $14.00 | 2023 | Kloxxado |
| Arbor Pharmaceuticals, INC. | $13.58 | 2021 | |
| Tolmar, INC. | $13.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hettler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.